Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
10:50am, Thursday, 11'th Aug 2022
The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
12:14pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus
02:53pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.
Teva Pharmaceutical: A Gem Among Generic Pharmaceutical Companies
05:25am, Sunday, 07'th Aug 2022 Seeking Alpha
Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. See why we believe there is huge potential for TEVA stock with target price of $25.
There are three reasons health care is the market's best sector today. These eight stocks are the most worry-free.
02:22pm, Saturday, 06'th Aug 2022 MarketWatch
Health-care stocks have both growth and defensive characteristics.
7 Cheap Blue-Chip Stocks to Buy Before They Rebound
08:00am, Friday, 05'th Aug 2022
Trying to find a good bargain seems tough these days, but there are certainly opportunities for savvy investors. Looking for cheap blue-chip stocks to buy before they rebound is a smart strategy right
Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?
10:20am, Thursday, 04'th Aug 2022 Zacks Investment Research
Smart Beta ETF report for MOAT
Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?
10:20am, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Style Box ETF report for MOAT
These eight health-care stocks can keep you invested in the market with less worry
10:52am, Tuesday, 02'nd Aug 2022
You're tempted to increase exposure to stocks because of the market's strength. But you're still gun shy because of the painful selloff.
Good News for Retirees: Lower Medicare Part B Premiums Could Be Coming
09:55am, Sunday, 31'st Jul 2022 The Motley Fool
Bad news for Biogen could translate to lower Medicare Part B premiums for seniors.
AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag
07:40pm, Friday, 29'th Jul 2022 Zacks Investment Research
AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales. Shares decline in pre-market trading.
Biotech Stock Roundup: BMY, BIIB's Q2 Earnings, GILD's Updates & More
03:15pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Earnings updates from Bristol Myers (BMY) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
03:04pm, Tuesday, 26'th Jul 2022 Zacks Investment Research
Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
12:25pm, Tuesday, 26'th Jul 2022
Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
11:30am, Tuesday, 26'th Jul 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for tofersen
